The UK Medicines and Healthcare Products Regulatory Agency approved Etopan XL Tablets and Tarodent Mouthwash.
Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) has obtained marketing authorization for Etopan XL Tablets 600 mg (Etodolac) from the UK Medicines and Healthcare Products Regulatory Agency. Etodolac is a non-steroidal anti-inflammatory drug taken for acute or long-term use in rheumatoid arthritis and osteoarthritis. This is a generic version of Shire Pharmaceuticals Group plc’s (LSE:SHP; Nasdaq:SHPGY; TSX:SHQ) Lodine, which Taro said had $18 million in annual sales in the UK.
Taro also obtained marketing approval for Tarodent 0.2% Mouthwash, an over-the-counter product. This is a generic alternative to Corsodyl Mouthwash, which is marketed in the UK by GlaxoSmithKline Consumer Healthcare.
Taro has a market cap of almost $300 million, following a 27% drop in its share since January.
Published by Globes [online], Israel business news - www.globes.co.il - on November 14, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006